Telix Pharmaceuticals Limited

TLX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$9.05-0.55%

2026-11-02

Financials

Valuation Metrics

Telix Pharmaceuticals Limited's Market Cap is $3.07B. Ranked #1667 of 3,116 in US market (top 53%), #589 of 1,472 on NASDAQ (top 40%), #98 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$3.07B	US#1,667/3,116 Sec#98/265
Revenue	$777M	US#2,010/3,116 Sec#62/265
Net Income	$-7M	US—/3,116 Sec—/265
Total Assets	$1.19B	US#2,387/3,116 Sec#88/265
Net Assets	$417M	US#2,335/3,116 Sec#128/265
Value
P/B	7.36x	US#2,497/3,116 Sec#179/265
P/S	3.94x	US#2,098/3,116 Sec#67/265
EV/EBITDA	65.89x	US#2,389/3,116 Sec#76/265
FCF Yield	-1.74%	US—/3,116 Sec—/265
Profitability
ROE	-1.65%	US#2,167/3,116 Sec#67/265
ROA	-0.58%	US#2,275/3,116 Sec#74/265
Op. Margin	2.21%	US#2,209/3,116 Sec#75/265
Revenue Growth	53.91%	US#205/3,116 Sec#47/265
Earnings Growth	-121.41%	US#1,877/3,116 Sec#56/265
Financial Health
Debt Ratio	184.59%	US#1,705/3,116 Sec#194/265
Total Debt	$469M	US#1,892/3,116 Sec#64/265
FCF	$-53M	US#2,530/3,116 Sec#114/265
Cash	$142M	US#1,980/3,116 Sec#137/265
Current Ratio	1.43x	US#1,742/3,116 Sec#240/265
Net Debt/EBITDA	6.34x	US#2,181/3,116 Sec#79/265
Performance
1Y Return	-15.10%	US#2,158/3,116 Sec#172/265
1M Return	-14.22%	US#2,793/3,116 Sec#227/265
From 52W High	-30.97%	US#1,890/3,116 Sec#121/265
1Y MDD	-37.71%	US#1,933/3,116 Sec#122/265
Trading
Volume	244,003 shares	US#2,610/3,116 Sec#245/265
Trading Value	$2M	US#2,894/3,116 Sec#240/265
Per Share
EPS	$-0.02	US—/3,116 Sec—/265
BPS	$1.23	US#2,657/3,116 Sec#193/265